rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
1
|
pubmed:dateCreated |
2002-12-30
|
pubmed:abstractText |
Weekly paclitaxel alone has moderate activity in the salvage treatment of recurrent ovarian cancer and is associated with a favorable toxicity profile. Combination paclitaxel and carboplatin is a well-established first-line regimen for ovarian cancer. The purpose of this study was to evaluate weekly low-dose paclitaxel and carboplatin in recurrent ovarian or peritoneal cancer.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0090-8258
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
88
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
51-7
|
pubmed:dateRevised |
2006-4-24
|
pubmed:meshHeading |
pubmed-meshheading:12504627-Adult,
pubmed-meshheading:12504627-Aged,
pubmed-meshheading:12504627-Aged, 80 and over,
pubmed-meshheading:12504627-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12504627-Carboplatin,
pubmed-meshheading:12504627-Disease-Free Survival,
pubmed-meshheading:12504627-Dose-Response Relationship, Drug,
pubmed-meshheading:12504627-Drug Administration Schedule,
pubmed-meshheading:12504627-Female,
pubmed-meshheading:12504627-Humans,
pubmed-meshheading:12504627-Middle Aged,
pubmed-meshheading:12504627-Neoplasm Recurrence, Local,
pubmed-meshheading:12504627-Ovarian Neoplasms,
pubmed-meshheading:12504627-Paclitaxel,
pubmed-meshheading:12504627-Peritoneal Neoplasms
|
pubmed:year |
2003
|
pubmed:articleTitle |
Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer.
|
pubmed:affiliation |
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina 27710, USA. havri001@mc.duke.edu
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study,
Clinical Trial, Phase II
|